title: D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: a marker of metastatic risk.
abstract: BACKGROUND
  Approximately 4% of cutaneous squamous cell carcinomas (cSCCs) develop lymphatic metastases. The value of lymphatic endothelial markers to enhance the detection of lymphatic tumor invasion in cSCC has not been assessed previously.
  
  
  OBJECTIVE
  We sought to evaluate the use of the antibody D2-40, a podoplanin immunohistochemical marker, to identify tumor lymph vessel invasion in cSCC and to assess its expression in tumor cells.
  
  
  METHODS
  This was a retrospective case-control study. A series of 101 cSCC, including 51 cases that developed lymphatic metastatic spread (metastasizing cSCC [MSCC]) and 50 cases that resolved definitely after surgical excision (non-MSCC) were included in the study. Lymph vessel invasion using D2-40 was evaluated on all primary biopsy specimens. The percentage of tumor cells showing D2-40 positivity and intensity scoring were recorded. All the immunohistochemical findings were correlated with the clinicopathological features.
  
  
  RESULTS
  Lymph vessel invasion was observed in 8% of non-MSCCs and in 25.5% of MSCCs (P = .031). D2-40 expression was significantly increased, both in intensity (odds ratio 4.42 for intensity ++/+++) and in area (odds ratio 2.29 for area >10%), in MSCC when compared with non-MSCC. Interestingly, almost half (49%) of the MSCC had moderate to intense D2-40 positivity compared with 16% of non-MSCC. D2-40 immunohistochemical expression was increased in tumors with an infiltrative pattern of extension. In the multivariate analysis, histologically poorly differentiated tumors, recurrent lesions, and cSCC showing D2-40 overexpression (in intensity) were significantly associated with lymphatic metastases development (odds ratios 15.67, 14.72, and 6.07, respectively).
  
  
  CONCLUSIONS
  This was a retrospective study.
  
  
  CONCLUSIONS
  The expression of podoplanin associates with high metastatic risk in cSCC.
authors.affiliation: Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain. atoll@parcdesalutmar.cat
authors.forename: Agustí
authors.initials: A
authors.lastname: Toll
authors.forename: Javier
authors.initials: J
authors.lastname: Gimeno-Beltrán
authors.forename: Carla
authors.initials: C
authors.lastname: Ferrandiz-Pulido
authors.forename: Emili
authors.initials: E
authors.lastname: Masferrer
authors.forename: Mireia
authors.initials: M
authors.lastname: Yébenes
authors.forename: Anna
authors.initials: A
authors.lastname: Jucglà
authors.forename: Leandre
authors.initials: L
authors.lastname: Abal
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Martí
authors.forename: Onofre
authors.initials: O
authors.lastname: Sanmartín
authors.forename: Teresa
authors.initials: T
authors.lastname: Baró
authors.forename: Beatriz
authors.initials: B
authors.lastname: Casado
authors.forename: Alberto
authors.initials: A
authors.lastname: Gandarillas
authors.forename: Carlos
authors.initials: C
authors.lastname: Barranco
authors.forename: Irmgard
authors.initials: I
authors.lastname: Costa
authors.forename: Sergi
authors.initials: S
authors.lastname: Mojal
authors.forename: Vicenç
authors.initials: V
authors.lastname: García-Patos
authors.forename: Ramon M
authors.initials: RM
authors.lastname: Pujol
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000032:analysis / Q000096:biosynthesis*; D015415:Biomarkers / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000378:metabolism* / Q000556:secondary*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D012189:Retrospective Studies; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; C500987:monoclonal antibody D2-40